Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-Ornithine L-Aspartate and N-Acetylcysteine in HR+/HER2- Advanced Breast Cancer
NCT07117630Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of l-ornithine l-aspartate, acetylcysteine, pioglitazone in breast cancer, sponsored by Fudan University. Started Sep 2025; status: recruiting.
02
Drugs
l-ornithine l-aspartateacetylcysteinepioglitazone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07117630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117630.